<DOC>
	<DOCNO>NCT02097004</DOCNO>
	<brief_summary>A randomized , Open label , Single center , Prospective study compare efficacy safety Therapeutic Vaccination Intensified schedule plus Pegylated Interferon dual Therapy Seroclearance Hepatitis B virus Surface Antigen Patients Complete Virological Response Induced Entecavir</brief_summary>
	<brief_title>Study Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy Chronic Hepatitis B Infection</brief_title>
	<detailed_description>A randomized , Open label , Single center , Prospective study compare efficacy safety Therapeutic Vaccination Intensified schedule plus Pegylated Interferon dual Therapy Seroclearance Hepatitis B virus Surface Antigen Patients Complete Virological Response Induced Entecavir ( E + VIP )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>1 . Age 20 75 yearold 2 . HBsAgpositive &gt; 6 month apart ( medical history alternative ) 3 . Currently treat entecavir 0.5 mg/day 18 month 4 . Undetectable HBV DNA serum ( &lt; 20IU/mL ) HBeAgnegative positive &gt; 1year 5 . HBsAg titer &lt; 3,000 IU/mL 6 . ALT &lt; 300 IU/L 7 . Signed write informed consent instruct objective procedure clinical study 1 . Patients decompensated liver cirrhosis , one follow ① Serum bilirubin &gt; 3 mg/dL ② Prothrombin time &gt; 6 second prolonged INR &gt; 2.3 ③ Serum albumin &lt; 2.8 g/dL ④ History ascites , variceal hemorrhage , hepatic encephalopathy ⑤ ChildPugh score ≥7 ( ChildPugh class B C ) 2 . Patients evidence renal insufficiency define serum creatinine &gt; 1.5 mg/dL 3 . Patients psychological problem include depression 4 . Patients previous/current significant comorbidities include congestive heart failure , chronic kidney disease , hematologic disease malignancy include hepatocellular carcinoma ( patient malignancy cure 5 year screen enrol ) 5 . Patients seropositivity antiHCV , antiHDV antiHIV 6 . Patients excessive alcohol consumption ( &gt; 30 g/day ) 7 . Patients evidence autoimmune hepatitis , hemochromatosis Wilson 's disease 8 . Pregnant breast feeding female plan pregnancy contraception 9 . Patients disease may deteriorate interferon therapy ( eg , autoimmune thyroiditis ) 10 . Patients psoriasis 11 . Patients history antiviralresistant HBV previous treatment oral antiviral agent 12 . Previous diagnosis immunodeficiency concomitant treatment immune suppressive agent previous organ transplantation Recipients 13 . Patients history hypersensitivity study drug 14 . Uncontrollable seizure , convulsion and/or central nervous system disorder 15 . Patients severe bone marrow disorder history hypersensitivity biologic agent vaccine . 16 . Neutrophil count &lt; 1,500/mm3 platelet count &lt; 75,000/mm3 hemoglobin &lt; 10 g/dl 17 . Patients Pulmonary disease ( case history pulmonary disease complete recovery , enrollment investigator 's discretion ) 18 . Patients fever ≥ 38 °C baseline 19 . Patients risk febrile response systemic reaction 20 . Patients investigator deems inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>chronic hepatitis B</keyword>
	<keyword>Pegasys</keyword>
	<keyword>Euvax B</keyword>
	<keyword>Baracrude</keyword>
</DOC>